Alkermes plc. Held-to-maturity Securities, Debt Maturities, Fair Value (Deprecated 2013-01-31)
Alkermes plc. (ALKS) had Held-to-maturity Securities, Debt Maturities, Fair Value (Deprecated 2013-01-31) of $1.20 million as of 2013-06-30, per its 10-Q filed 2013-07-25.
Discontinued › Notes › Investments › Debt and Equity Securities › Debt Securities, Held-to-Maturity, Maturity › Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date
us-gaap:HeldToMaturitySecuritiesDebtMaturitiesFairValue · last filed 2013-07-25
- 2013-06-30: Held-to-maturity Securities, Debt Maturities, Fair Value (Deprecated 2013-01-31) $1.20M.
- 2013-03-31: Held-to-maturity Securities, Debt Maturities, Fair Value (Deprecated 2013-01-31) $1.20M.
- 2012-09-30: Held-to-maturity Securities, Debt Maturities, Fair Value (Deprecated 2013-01-31) $1.20M.
- 2012-06-30: Held-to-maturity Securities, Debt Maturities, Fair Value (Deprecated 2013-01-31) $5.86M.
| Period end | Held-to-maturity Securities, Debt Maturities, Fair Value (Deprecated 2013-01-31) |
|---|---|
| 2013-06-30 | $1.20M 10-Q · filed 2013-07-25 |
| 2013-03-31 | $1.20M 10-K · filed 2013-05-23 |
| 2012-09-30 | $1.20M 10-Q · filed 2013-01-31 |
| 2012-06-30 | $5.86M 10-Q · filed 2012-07-26 |
| 2012-03-31 | $5.85M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |